Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

NXTC

Nextcure Inc

Jan 23 • 01:45PM ET

11.92

-0.73 -5.77 %

Healthcare • Biotechnology • USA • NASD

Today, 7:06 AMNextCure issues Jan. 23 business update providing timelines for SIM0505 and LNCB74 ADC Phase 1 programs and reporting a preliminary unaudited year-end 2025 cash position and runway.

Peers: SRPT ALLO FOLD XNCR ANAB IGMS NKTR ONCT ACHV ANGO

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-24.19	Insider Own	45.93%	Shs Outstand	2.68M	Perf Week	-7.38%
Market Cap	41.79M	Forward P/E	-	EPS next Y	-8.22	Insider Trans	0.00%	Shs Float	1.90M	Perf Month	3.11%
Enterprise Value	17.43M	PEG	-	EPS next Q	-2.29	Inst Own	18.74%	Short Float	1.71%	Perf Quarter	32.00%
Income	-58.01M	P/S	-	EPS this Y	26.20%	Inst Trans	7.18%	Short Ratio	0.72	Perf Half Y	126.62%
Sales	0.00M	P/B	1.35	EPS next Y	53.34%	ROA	-89.28%	Short Interest	0.03M	Perf YTD	-16.00%
Book/sh	8.84	P/C	1.44	EPS next 5Y	47.43%	ROE	-116.91%	52W High	15.74 -24.27%	Perf Year	24.71%
Cash/sh	8.30	P/FCF	-	EPS past 3/5Y	7.48% 1.53%	ROIC	-206.76%	52W Low	2.69 343.45%	Perf 3Y	-33.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.98% 8.56%	Perf 5Y	-91.93%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	3.78%	Oper. Margin	-	ATR (14)	1.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.97	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.75	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.97	EPS Q/Q	34.90%	SMA20	-9.72%	Beta	1.55	Target Price	17.67
Payout	-	Debt/Eq	0.20	Sales Q/Q	-	SMA50	-1.60%	Rel Volume	0.60	Prev Close	12.65
Employees	43	LT Debt/Eq	0.19	Earnings	Nov 05 AMC	SMA200	58.52%	Avg Volume	45.38K	Price	11.92
IPO	May 09, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	19.16% -	Trades		Volume	18,724	Change	-5.77%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-25	Upgrade	Ladenburg Thalmann	Neutral → Buy	$18
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy	$16
Mar-05-21	Upgrade	Truist	Hold → Buy	$19
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy	$17
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral	$62 → $40
May-26-20	Initiated	JMP Securities	Mkt Outperform	$55
Mar-24-20	Initiated	The Benchmark Company	Buy	$55
Mar-02-20	Initiated	ROTH Capital	Buy	$80
Jan-13-20	Initiated	SunTrust	Buy	$78
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy	$61
Jul-09-19	Initiated	BofA/Merrill	Buy	$25
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26
Jun-03-19	Initiated	Morgan Stanley	Overweight	$25

Show Previous Ratings

Today 07:00AM	NextCure Provides Business Update (GlobeNewswire) -5.77%
Nov-20-25 08:00AM	NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-17-25 08:00AM	NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts (GlobeNewswire)
Nov-12-25 08:00AM	NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules (GlobeNewswire) +9.04%
Nov-11-25 09:55AM	Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect? (Zacks)
04:05PM	Loading…
Nov-05-25 04:05PM	NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-16-25 08:05AM	NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States (GlobeNewswire) +27.75%
Sep-04-25 07:00AM	NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-07-25 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire) +17.30%
Jun-17-25 05:34AM	NextCure and Simcere partner to develop SIM0505 for solid tumours (Pharmaceutical Technology) -10.08%
Jun-16-25 07:05AM	NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 (GlobeNewswire) -26.27%
May-29-25 11:03PM	NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 (Insider Monkey) +6.41%
04:05PM	NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 (GlobeNewswire)
May-01-25 04:05PM	NextCure Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -7.81%
07:00AM	Loading…
Apr-04-25 07:00AM	NextCure to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-25 04:05PM	NextCure Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire) +5.20%
Jan-10-25 08:05AM	NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers (GlobeNewswire) -6.11%
Dec-10-24 08:05AM	NextCure Announces Acceptance of IND Application for LNCB74 (GlobeNewswire)
Nov-26-24 07:00AM	NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-19-24 08:05AM	Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire)
Nov-08-24 06:18AM	NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space (FierceBiotech.com)
Nov-07-24 04:05PM	NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 04:05PM	NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-24 09:05AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-16-24 08:05AM	NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 (GlobeNewswire)
Aug-01-24 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-20-24 04:10PM	NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire) +13.64% +8.00%
May-30-24 04:05PM	NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 (GlobeNewswire)
May-02-24 09:57PM	NXTC Stock Earnings: NextCure Misses EPS for Q1 2024 (InvestorPlace) +8.76%
04:05PM	Loading…
04:05PM	NextCure Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:05PM	NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire) -5.88% -10.42%
Apr-08-24 07:00AM	NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 (GlobeNewswire) -5.96%
Apr-04-24 07:05AM	NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board (GlobeNewswire) -10.00%
Apr-02-24 07:00AM	NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +7.79%
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 10:54PM	NXTC Stock Earnings: NextCure Beats EPS for Q4 2023 (InvestorPlace) +19.15% +13.10%
11:22AM	NextCure to lay off 37% of staff, dial back research plans (BioPharma Dive)
08:55AM	NextCure Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 08:05AM	NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances (GlobeNewswire)
Jan-18-24 04:05PM	NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders (GlobeNewswire)
Dec-25-23 09:55AM	Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing (Zacks)
Dec-21-23 07:05AM	NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury (GlobeNewswire)
Dec-15-23 11:23AM	NextCure (NXTC) Down on Shelving Plans to Develop Candidate (Zacks) -5.13%
Dec-14-23 09:14AM	NextCure jettisons monoclonal antibody to focus on ADC aimed at same target (FierceBiotech.com) -19.31%
06:45AM	NextCure Provides Year-End Clinical Pipeline Updates (GlobeNewswire)
Nov-20-23 07:00AM	NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-23 04:05PM	NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML (GlobeNewswire) +5.93% -6.40%
Nov-07-23 12:00PM	All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy (Zacks)
Nov-02-23 06:07PM	NextCure Inc (NXTC) Reports Q3 2023 Financial Results (GuruFocus.com) +9.35%
04:05PM	NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-17-23 08:05AM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-26-23 04:05PM	NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimers Disease (GlobeNewswire)
Sep-12-23 08:05AM	A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC (GlobeNewswire)
Sep-07-23 04:05PM	NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen (GlobeNewswire)
Sep-05-23 04:05PM	Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease (GlobeNewswire)
Aug-31-23 07:00AM	NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-21-23 04:05PM	NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting (GlobeNewswire)
May-11-23 01:58PM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
May-09-23 07:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-04-23 04:05PM	NextCure Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-11-23 07:00AM	NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-02-23 04:05PM	NextCure Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire)
Feb-07-23 07:00AM	NextCure to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-02-22 10:59AM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-22-22 08:00AM	NextCure to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-16-22 08:09AM	NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates (Benzinga) -6.02%
Nov-15-22 04:30PM	NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates (GlobeNewswire)
Nov-07-22 08:05AM	NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -13.64%
Nov-03-22 04:15PM	NextCure Provides Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.12%
09:15AM	NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-27-22 04:05PM	NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board (GlobeNewswire)
Oct-05-22 12:00PM	NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
08:15AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-22 04:05PM	NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors (GlobeNewswire) +9.42%
Sep-22-22 08:00AM	NextCure to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -12.64%
Aug-22-22 06:23AM	With 37% ownership, NextCure, Inc. (NASDAQ:NXTC) has piqued the interest of institutional investors (Simply Wall St.) -5.45%
Aug-04-22 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +6.32%
Jul-06-22 08:00AM	NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation (GlobeNewswire)
Jun-27-22 08:00AM	NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM (GlobeNewswire)
Jun-25-22 10:26AM	We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-22 08:00AM	Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting (GlobeNewswire)
Jun-08-22 08:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-11-22 08:17AM	NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
May-05-22 04:05PM	NextCure Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-03-22 08:00AM	NextCure to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-19-22 07:30AM	NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation (GlobeNewswire)
Apr-05-22 08:00AM	NextCure to Present at 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-15-22 06:21AM	What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares? (Simply Wall St.)
Mar-03-22 04:05PM	NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-08-22 08:00AM	NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Dec-13-21 08:05AM	NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-30-21 08:00AM	NextCure to Present at The JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-22-21 08:00AM	NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-13-21 02:00PM	NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Nov-04-21 04:05PM	NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
09:15AM	NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-21 08:00AM	NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021 (GlobeNewswire)
Oct-19-21 08:05AM	NextCure Announces Three New Members of its Scientific Advisory Board (GlobeNewswire)

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NXTC

Nextcure Inc

Upgrade your FINVIZ experience